Caladrius Biosciences, Inc. (CLBS) Upgraded to Hold by Zacks Investment Research
Caladrius Biosciences, Inc. (NASDAQ:CLBS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, May 22nd.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Separately, HC Wainwright set a $7.00 price target on Caladrius Biosciences and gave the company a “buy” rating in a research report on Friday, May 19th.
Caladrius Biosciences (NASDAQ CLBS) traded down 3.84% during mid-day trading on Monday, reaching $4.51. 50,158 shares of the company were exchanged. The stock’s 50-day moving average is $4.83 and its 200-day moving average is $4.46. Caladrius Biosciences has a 12 month low of $2.65 and a 12 month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings results on Thursday, May 18th. The biotechnology company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.40. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 678.79%. The company had revenue of $7.92 million for the quarter, compared to analyst estimates of $9.50 million. Analysts predict that Caladrius Biosciences will post ($3.95) earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in CLBS. KCG Holdings Inc. raised its position in shares of Caladrius Biosciences by 74.6% in the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock worth $183,000 after buying an additional 15,501 shares during the period. Renaissance Technologies LLC raised its position in shares of Caladrius Biosciences by 149.2% in the fourth quarter. Renaissance Technologies LLC now owns 72,652 shares of the biotechnology company’s stock worth $206,000 after buying an additional 43,500 shares during the period. Knoll Capital Management LP purchased a new position in shares of Caladrius Biosciences during the third quarter worth $266,000. Finally, Vanguard Group Inc. raised its position in shares of Caladrius Biosciences by 39.3% in the first quarter. Vanguard Group Inc. now owns 151,217 shares of the biotechnology company’s stock worth $761,000 after buying an additional 42,644 shares during the period. Hedge funds and other institutional investors own 5.59% of the company’s stock.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.